BioNet and BIA Separations, now part of Sartorius, have announced the successful development of an optimized mRNA manufacturing process.

Orbit, a new business accommodation space hosted by Durham University, has opened a new facility in NETPark, one of the UK’s leading science and technology parks.

The BioPhase 8800 system ushers in a new phase of biologic characterization, empowering scientists to analyze more samples and molecules to meet next-gen drug development challenges.

Personalized vaccine strategies minimize deaths and case numbers in a Coronavirus wave of "Variants of Concern" when vaccine supply is limited, a modelling study from Switzerland predicts

Uniqsis makes flow chemistry accessible to everyone, while at the same time catering for multi-step and automated reactions sequences, through the availability of an expanding suite of affordable 'plug and play' reactor modules.

The Native Antigen Company, part of LGC Clinical Diagnostics and a supplier of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, won ‘The Best COVID-19 Responder’ at OBN 2020 Awards.

The Thermo Scientific TSX Series Ultra-Low Temperature Freezers have been fully upgraded to include additional functionality to provide research, pharmaceutical manufacturing, clinical, biorepository and industrial laboratories with safeguards to deliver environmentally sustainable protection of materials.

Scientific Products has announced one of the world’s largest simultaneous installations of commercial lyophilizers for use in the production of diagnostic tests. The order, for SP lyophilizers, was made last year in response to the need for an increase in SARS-CoV-2 testing.

Oxford Immunotec has announced that its T-SPOT® Discovery SARS-CoV-2 kit is being used for T cell testing in the UK COVID-19 Human Challenge Study, a national collaboration including the UK government, the NHS, academia and the private sector.

Memo Therapeutics AG has announced that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).